"One of the most amazing things I’ve ever seen," clinician-scientist Samuel Hume wrote alongside a video clip posted on X.
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic ...
Morning Overview on MSN
The first-ever drug aimed at pancreatic cancer’s ‘untreatable’ KRAS mutation just cleared the FDA’s safe-to-proceed letter — full phase 1/2 results drop at ASCO this ...
For more than four decades, oncologists have known that a single protein drives nearly all pancreatic cancers, and for just ...
Around 97% of patients with advanced pancreatic cancer die within five years. Researchers have figured out a way to target ...
A new once-daily pill almost doubled the survival time for patients battling an aggressive and advanced form of pancreatic ...
A phase 3 clinical trial has demonstrated that daraxonrasib significantly improved overall survival and progression-free ...
A new era in the treatment of deadly pancreatic cancer was heralded by scientists this week, thanks to science by the ...
Two KRAS-targeted strategies are starting to reshape treatment for metastatic pancreatic cancer after decades of limited progress with chemotherapy.
FDA grants Fast Track designation to VS-7375, an oral investigational KRAS G12D inhibitor, for locally advanced or metastatic ...
The landmark success of a drug against an ‘undruggable’ cancer is spurring fresh optimism in the quest to treat seemingly ...
FDA fast-tracks VS-7375, an oral KRAS G12D inhibitor, opening new hope for pretreated advanced NSCLC and fueling pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results